Trials / Conditions / Influenza Immunization

Influenza Immunization

20 registered clinical trials studyying Influenza Immunization — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe NCT07282795	Sanofi	—
Active Not Recruiting	Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years NCT06727058	Sanofi Pasteur, a Sanofi Company	Phase 1 / Phase 2
Active Not Recruiting	Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvante NCT06695117	Sanofi	Phase 1 / Phase 2
Completed	A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the NCT06765187	Sanofi	—
Active Not Recruiting	Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvante NCT06695130	Sanofi	Phase 1 / Phase 2
Completed	Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participant NCT06800885	Sanofi Pasteur, a Sanofi Company	—
Completed	A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Age NCT06361875	Sanofi Pasteur, a Sanofi Company	Phase 1 / Phase 2
Completed	Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutin NCT05829356	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age NCT05650554	Sanofi Pasteur, a Sanofi Company	Phase 1 / Phase 2
Completed	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age NCT05624606	Sanofi Pasteur, a Sanofi Company	Phase 1 / Phase 2
Terminated	Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Va NCT05513391	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. NCT05513053	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age NCT05553301	Sanofi Pasteur, a Sanofi Company	Phase 1 / Phase 2
Completed	Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of NCT05426174	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants NCT06118151	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations NCT05050318	Sanofi Pasteur, a Sanofi Company	Phase 4
Completed	Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomi NCT04969276	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV- NCT04498832	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations NCT04551677	Sanofi Pasteur, a Sanofi Company	Phase 4
Completed	Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV- NCT04024228	Sanofi Pasteur, a Sanofi Company	Phase 3